← board
ELUT
distress 3/10 · well-funded / low risk$0.93-2%today-62% from 52w high
Lead: breast reconstruction infections
Revenue
pre-revenue
Liquidity
$28M
Runway
0.7 yrs
Shares 1y
—
Price & events
-7.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.9%
1D
-2.9%
1W
-6.8%
1M
-19.0%
3M
-7.7%
6M
-55.6%
1Y
-75.2%
2Y
-88.6%
5Y
-92.9%
All
Overview
- Volume
- 87.40K
- 52 Week Range
- $0.51 – $2.45
- Float Shares
- 26.05M
- Short %
- 0.14%
- % Held by Insiders
- 3.51%
- % Held by Institutions
- 45.68%
- RVOL
- 0.87x
- Beta
- 0.85
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- first half of 2027Guided 55%conferencedata presentationsecondaryNXT-41x · Planned market launchSEC 8-K
- 2026-08-14Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-10-01partnershipSale of CIED business to Boston Scientific for $88M closedSEC 8-K
- 2025-09-08partnershipCanGaroo · Asset purchase agreement with Boston Scientific for CIED business.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $5 (+436% upside) · 1 analysts
- 2025-09-10Lake StreetBuy
- 2025-05-09Lake StreetBuy
- 2025-03-07Cantor FitzgeraldOverweight
- 2024-11-15Cantor FitzgeraldOverweight
- 2024-09-06Cantor FitzgeraldOverweight
- 2024-08-08Cantor FitzgeraldOverweight
Competitors — breast reconstruction infections
- none identified
Recent news
- 2026-07-21Elutia Sells SimpliDerm Business for Up to $11M to Fund NXT-41x Launch in $1.5B Plastic Surgery Market 1 - Minichart
- 2026-07-20Elutia Divests SimpliDerm Assets to Refocus Strategy - TipRanks
- 2026-07-18Lake Street Reaffirms Their Buy Rating on Elutia (ELUT) - The Globe and Mail
- 2026-07-17Elutia Sheds Legacy Business to Chase $1.5 Billion Market Opportunity - Benzinga
- 2026-07-17Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch - Sahm
- 2026-07-17Elutia to sell SimpliDerm business for up to $11 million By Investing.com - Investing.com South Africa
- 2026-07-16Elutia Agrees to Sell SimpliDerm for Up to $11 Million - marketscreener.com
- 2026-07-16Elutia to sell SimpliDerm business for up to $11 million - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.